Van Berkom & Associates Inc. Sells 346,150 Shares of RadNet, Inc. $RDNT

Van Berkom & Associates Inc. cut its stake in RadNet, Inc. (NASDAQ:RDNT) by 29.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 846,918 shares of the medical research company’s stock after selling 346,150 shares during the quarter. RadNet accounts for 2.1% of Van Berkom & Associates Inc.’s holdings, making the stock its 28th biggest position. Van Berkom & Associates Inc. owned 1.08% of RadNet worth $58,387,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. Farther Finance Advisors LLC boosted its stake in RadNet by 60.2% during the 3rd quarter. Farther Finance Advisors LLC now owns 596 shares of the medical research company’s stock worth $41,000 after acquiring an additional 224 shares during the last quarter. Parallel Advisors LLC grew its holdings in RadNet by 80.0% during the first quarter. Parallel Advisors LLC now owns 1,114 shares of the medical research company’s stock valued at $62,000 after purchasing an additional 495 shares during the period. GAMMA Investing LLC grew its holdings in RadNet by 10.6% during the third quarter. GAMMA Investing LLC now owns 2,321 shares of the medical research company’s stock valued at $160,000 after purchasing an additional 222 shares during the period. Nykredit A S bought a new stake in RadNet in the second quarter valued at approximately $153,000. Finally, Modera Wealth Management LLC bought a new stake in RadNet in the third quarter valued at approximately $207,000. 77.90% of the stock is owned by institutional investors.

RadNet Stock Up 3.1%

Shares of RadNet stock opened at $78.38 on Tuesday. RadNet, Inc. has a 1 year low of $50.82 and a 1 year high of $85.84. The business has a 50-day moving average of $72.64 and a two-hundred day moving average of $65.43. The company has a market capitalization of $6.17 billion, a P/E ratio of -290.29 and a beta of 1.42. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.48 and a quick ratio of 1.48.

RadNet (NASDAQ:RDNT) last released its quarterly earnings results on Sunday, November 8th. The medical research company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.08. RadNet had a positive return on equity of 2.61% and a negative net margin of 0.93%. The company had revenue of $638.26 million for the quarter, compared to analyst estimates of $639.97 million. During the same quarter last year, the firm posted $0.20 earnings per share. RadNet’s revenue was up 22.1% compared to the same quarter last year. As a group, equities analysts predict that RadNet, Inc. will post 0.49 EPS for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on RDNT. Truist Financial increased their target price on shares of RadNet from $90.00 to $94.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Barclays lifted their price target on shares of RadNet from $65.00 to $79.00 and gave the stock an “overweight” rating in a research report on Friday, August 28th. Zacks Research raised shares of RadNet from a “hold” rating to a “strong-buy” rating in a report on Friday, October 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of RadNet in a report on Wednesday, November 4th. Finally, Jefferies Financial Group restated a “buy” rating on shares of RadNet in a research report on Friday, July 31st. Three investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, RadNet has a consensus rating of “Buy” and an average price target of $90.00.

More RadNet News

Here are the key news stories impacting RadNet this week:

• Positive Sentiment: RadNet reported Q3 EPS of $0.30, beating the $0.22 consensus estimate by 35%. Revenue rose 22.1% year over year to $638.26 million, while the company also reported record quarterly revenue and adjusted EBITDA. RadNet Q3 financial results and revised guidance
• Positive Sentiment: The company raised its 2026 revenue guidance to $2.5 billion–$2.6 billion, versus analyst expectations of about $2.5 billion. This marked its third consecutive quarterly guidance increase. RadNet Q3 earnings and guidance
• Negative Sentiment: Revenue of $638.26 million narrowly missed the $639.97 million consensus estimate, tempering an otherwise strong quarter. RadNet earnings report

RadNet Company Profile

RadNet, Inc operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging.

The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.

RadNet also develops digital health and artificial intelligence solutions through its subsidiary DeepHealth, including technology intended to support imaging workflows and assist with image analysis.